Skip to main content
. 2023 Dec 1;78(2):113–122. doi: 10.1111/pcn.13615

Fig. 2.

Fig. 2

Patient disposition. Percentages are based on the number of subjects in treatment group; Safety analysis set comprise subjects who have received at least one dose of investigational product in Phase B; Full analysis set comprise subjects who have received at least one dose of investigational product in Phase B, and from whom MADRS total scores have been obtained at baseline and at least one post baseline timepoint.